Daunorubicin is an anthracycline antibiotic widely used in cancer treatment, particularly for leukemias such as Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia. It works by intercalating into DNA and inhibiting topoisomerase II, thereby preventing cancer cell replication. Daunorubicin was first discovered in the 1960s from the bacterium Streptomyces peucetius, isolated by researchers in Italy at the pharmaceutical company Farmitalia, marking a major breakthrough in chemotherapy. It was one of the earliest anthracyclines introduced into clinical practice and paved the way for the development of related drugs like Doxorubicin, significantly improving survival rates in hematologic cancers.
BRAND NAMES
Cerubidine – the most widely recognized brand name for intravenous use
Daunomycin – an alternative brand name used in certain regions
Daunorubicin Hydrochloride Injection – generic formulations.
MECHANISM OF ACTION
Daunorubicin is an anthracycline chemotherapeutic agent that exerts its cytotoxic effects through multiple mechanisms. It intercalates between DNA base pairs, disrupting the structure of the DNA helix and inhibiting DNA and RNA synthesis. Additionally, daunorubicin inhibits topoisomerase II, preventing the relaxation of supercoiled DNA required for replication and transcription, which leads to DNA strand breaks.
PHARMACOKINETICS
Absorption
Daunorubicin is administered intravenously, so it bypasses gastrointestinal absorption, resulting in 100% bioavailability. Because it is not given orally, absorption variability is not a concern, and plasma concentrations are immediately achieved after infusion, allowing for predictable therapeutic and toxic effects.
Distribution
Daunorubicin has an apparent volume of distribution (Vd) of approximately 30–50 L/m², indicating extensive distribution into tissues beyond the plasma. High tissue uptake, especially in the heart, liver, and kidneys, contributes to both its therapeutic efficacy against rapidly dividing cells and its dose-dependent toxicities, particularly cardiotoxicity.
Metabolism
Daunorubicin is primarily metabolized in the liver through reduction and hydrolysis, forming its major active metabolite, daunorubicinol. This metabolite retains antineoplastic activity but also contributes to cardiotoxicity. Metabolism occurs via cytosolic enzymes, and both the parent drug and metabolite undergo enterohepatic circulation, which can prolong tissue exposure.
Elimination
Daunorubicin and its metabolite, daunorubicinol, are primarily eliminated via the bile into the feces, with only a small fraction (<10%) excreted in the urine. The drug exhibits triphasic plasma clearance, with an initial rapid distribution phase, an intermediate phase, and a prolonged terminal elimination phase.
PHARMACODYNAMICS
Daunorubicin intercalates DNA and inhibits topoisomerase II, blocking DNA replication and RNA transcription. It also generates reactive oxygen species, leading to apoptosis of rapidly dividing cancer cells. Its effects are dose-dependent, with higher cumulative doses increasing the risk of cardiotoxicity.
ADMINISTRATION
Daunorubicin is given intravenously, usually as part of combination chemotherapy. Doses are calculated by body surface area, and patients are monitored for cardiac function, blood counts, and liver function.
DOSAGE AND STRENGTH
Daunorubicin is given intravenously, and its dosage depends on the type of leukemia and patient factors. For Acute Myeloid Leukemia, it is typically administered at 45–90 mg/m² daily for 1–3 days, while for Acute Lymphoblastic Leukemia, doses of about 25–45 mg/m² are used according to treatment protocols. It is available in injection forms such as 20 mg, 40 mg, and 50 mg vials, and dosing is carefully calculated based on body surface area with limits due to potential cardiotoxicity.
DRUG INTERACTIONS
Daunorubicin interacts with several drugs that can affect its efficacy and toxicity. Concomitant use with other cardiotoxic agents such as trastuzumab or cyclophosphamide can increase the risk of cardiac damage, while CYP3A4 inhibitors or inducers may alter daunorubicin metabolism, leading to higher toxicity or reduced effectiveness.
FOOD INTERACTIONS
Daunorubicin is administered intravenously, so its absorption and efficacy are not affected by food. There are no known food interactions, and patients can eat normally during treatment. The focus remains on hydration and nutritional support to help tolerate chemotherapy and maintain overall health.
CONTRAINDICATIONS
Daunorubicin is contraindicated in patients with a known hypersensitivity to daunorubicin or other anthracycline antibiotics, as allergic reactions can be severe. It should not be administered to individuals with severe myelosuppression unrelated to leukemia, as this can exacerbate bone marrow suppression and increase the risk of infection or bleeding.
SIDE EFFECTS
Nausea and vomiting
Loss of appetite
Fatigue and weakness
Hair loss (alopecia)
Mouth sores (stomatitis)
Diarrhea
OVER DOSAGE
Overdosage of daunorubicin is a serious medical emergency that can lead to life-threatening toxicity. The most significant effects are severe myelosuppression, resulting in neutropenia, anemia, and thrombocytopenia, which greatly increase the risk of infections, bleeding, and fatigue.
TOXICITY
Daunorubicin toxicity primarily affects the heart, bone marrow, and gastrointestinal system. Its most serious and dose-dependent toxicity is cardiotoxicity, which can manifest as arrhythmias, left ventricular dysfunction, or congestive heart failure, with risk increasing in patients with prior anthracycline exposure, mediastinal radiation, or pre-existing heart disease. Myelosuppression is common and clinically significant, leading to neutropenia, anemia, and thrombocytopenia, which increase susceptibility to infections and bleeding.
